πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs
7,238

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Page 71 of 151

  1. KEYTRUDA 25 mg/mL concentrate for solution for infusion, TransCon TLR7/8 Agonist

    Lacuna Pharma Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  2. KEYTRUDA 25 mg/mL concentrate for solution for infusion, evorpacept

    Wuhan Createrna Science and Technology Co., Ltd

    metastatic or unresectable, recurrent HNSCC

    phase 2 small molecule active

    1 trial

  3. KEYTRUDA 25 mg/mL concentrate for solution for infusion., Darleukin, Fibromun

    Philogen S.p.A.

    Patients with diagnosis of unresectable clinical stage III or IV metastatic melanoma, with presence of injectable cutaneous, subcutaneous or nodal lesions and resistant to or progressing upon anti-PD1 immunotherapy

    phase 2 small molecule active

    1 trial

  4. KEYTRUDA 25 mg/mL concentrate for solution for infusion., LIBTAYO 350 mg concentrate for solution for infusion.

    Ningbo Cancer Hospital

    METAREM:Patients with advanced cancer, as defined as unresectable locally advanced malignancies or metastatic cancers (including leukemias and lymphomas). META-1: Patients in first-line therapy for advanced metastatic NSCLC with PD-L1 Tumor Proportion Score (TPS) >50%, without EGFR/ ALK/ ROS1 mutations and irrespective of their histological subtype (squamous or non-squamous)

    phase 2 small molecule active

    1 trial

  5. KEYTRUDA 25 mg/mL concentrate for solution for infusion., MK-3120, ENFORTUMAB VEDOTIN

    Merck Sharp and Dohme

    Urothelial carcinoma

    phase 2 small molecule active

    1 trial

  6. KEYTRUDA 25 mg/mL concentrate for solution for infusion., PARACETAMOL , CISPLATIN , FLUOROURACIL , -, MK-2870, CALCIUM FOLINATE , CALCIUM LEVOFOLINATE , -, MK-2870, -

    Merck Sharp and Dohme

    Colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC)

    phase 2 small molecule active

    1 trial

  7. KHK7580

    KYOWA KIRIN AUSTRALIA PTY LTD

    Hyperparathyroidism

    phase 2 small molecule completed

    1 trial

  8. KIMMTRAK 100 micrograms/0.5 mL concentrate for solution for infusion

    Disc Medicine

    Metastatic uveal melanoma with resectable liver metastasis and absence of extra-liver disease

    phase 2 small molecule active

    1 trial

  9. KIO-101

    KIORA PHARMACEUTICALS INC

    Dry Eye Disease

    phase 2 small molecule terminated

    1 trial

  10. KIO-104

    KIORA PHARMACEUTICALS INC

    Macular Edema

    phase 2 small molecule active

    1 trial

  11. KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S)

    KIORA PHARMACEUTICALS INC

    Persistent Corneal Epithelial Defect

    phase 2 small molecule completed

    1 trial

  12. KIO-301

    KIORA PHARMACEUTICALS INC

    Retinitis Pigmentosa

    phase 2 small molecule completed

    1 trial

  13. KN046

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  14. KN046

    Jiangsu Alphamab Biopharmaceuticals Co., Ltd

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  15. KN046 （PD-L1/CTLA4 BsAbοΌ‰

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Advanced HCC

    phase 2 small molecule terminated

    1 trial

  16. KPL-387

    Kiniksa Pharmaceuticals International, plc

    Well-Controlled Recurrent Pericarditis

    phase 2 small molecule active

    1 trial

  17. KPL-387

    Kiniksa Pharmaceuticals International, plc

    Recurrent Pericarditis

    phase 2 small molecule active

    1 trial

  18. KPL-404

    Kiniksa Pharmaceuticals International, plc

    Arthritis, Rheumatoid

    phase 2 small molecule completed

    1 trial

  19. KPL-716

    Kiniksa Pharmaceuticals International, plc

    Chronic Idiopathic Urticaria

    phase 2 small molecule completed

    1 trial

  20. KPL-914

    Kiniksa Pharmaceuticals International, plc

    Recurrent Pericarditis

    phase 2 small molecule completed

    1 trial

  21. KPT-8602

    Karyopharm Therapeutics Inc

    Relapsed/Refractory Multiple Myeloma (RRMM)

    phase 2 small molecule completed

    1 trial

  22. KT-621

    Kymera Therapeutics

    Atopic Dermatitis

    phase 2 small molecule active

    2 trials

  23. KT-621

    Kymera Therapeutics

    Eosinophilic Asthma

    phase 2 small molecule active

    1 trial

  24. KT-621, KT-621, KT-621, The placebo is used in the Double-blind, Placebo-controlled (DBPC) Treatment Period. Participants are randomly assigned to receive either KT-621 or a matching placebo. The placebo is designed to match the study drug in appearance and administration method to maintain blinding.

    Kymera Therapeutics

    Moderate to Severe Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  25. KT-621, Placebo oral tablet matched to KT-621, KT-621, KT-621

    Kymera Therapeutics

    Uncontrolled Moderate to Severe Eosinophilic Asthma

    phase 2 small molecule active

    1 trial

  26. KVD001 Injection

    Kalvista Pharmaceuticals (Ireland) Limited

    Diabetic Macular Edema

    phase 2 small molecule completed

    2 trials

  27. KVD824

    Kalvista Pharmaceuticals (Ireland) Limited

    Angioedema, Hereditary, Types I and II

    phase 2 small molecule terminated

    1 trial

  28. KVD900

    Kalvista Pharmaceuticals (Ireland) Limited

    Hereditary Angioedema

    phase 2 small molecule completed

    2 trials

  29. KW-2478

    KYOWA KIRIN AUSTRALIA PTY LTD

    Multiple Myeloma

    phase 2 small molecule completed

    1 trial

  30. KYV-101

    Kyverna Therapeutics

    Multiple Sclerosis, Primary Progressive

    phase 2 mab active

    1 trial

  31. KYV-101

    Kyverna Therapeutics

    Systemic Sclerosis

    phase 2 mab active

    1 trial

  32. KYV-101 anti-CD19 CAR-T cell therapy

    Kyverna Therapeutics

    Lupus Nephritis

    phase 2 mab active

    2 trials

  33. KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy

    Kyverna Therapeutics

    ANCA-IgG-positive ANCA Associated Vasculitis

    phase 2 small molecule active

    1 trial

  34. KYV101

    Kyverna Therapeutics

    Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  35. Kadcyla 160 mg powder for concentrate for solution for infusion., Tecentriq 1,200 mg concentrate for solution for infusion, Perjeta 420 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Metastatic Cancer

    phase 2 small molecule active

    1 trial

  36. Kanglaite

    The First People's Hospital of Lianyungang

    Head and Neck Cancer

    phase 2 small molecule completed

    1 trial

  37. Kapruvia 50 micrograms/mL solution for injection

    Fresenius Kabi Australia Pty Limited

    Pruritus, Chronic Kidney Diseases

    phase 2 small molecule active

    1 trial

  38. Karelizumab combined with etoposide and cisplatin

    Jian Li

    Carcinoma

    phase 2 small molecule active

    1 trial

  39. Kenacort-A 40, suspensie voor injectie 40 mg/ml, JNJ-81201887, Placebo to match Prednisone 20mg, 5mg, JNJ-81201887, Prednison acis 20 mg, Tabletten, Prednison acis 5 mg, Tabletten

    Janssen-Cilag International N.V.

    Geographic Atrophy

    phase 2 small molecule active

    1 trial

  40. Kerendia 10 mg film coated tablets, Kerendia 20 mg film-coated tablets, Finerenone/Kerendia 10mg and 20mg Placebo equal to test product except active substance, Empagliflozin/Jardiance 10mg Placebo equal to test product except active substance, Jardiance 10 mg film-coated tablets

    Bayer AG

    Chronic kidney disease in type 2 diabetes mellitus

    phase 2 small molecule active

    1 trial

  41. Kesimpta 20 mg solution for injection in pre-filled pen, Ocrevus 300 mg concentrate for solution for infusion, MabThera 500 mg concentrate for solution for infusion, MabThera 100 mg concentrate for solution for infusion, MabThera 100 mg concentrate for solution for infusion, Kesimpta 20 mg solution for injection in pre-filled syringe, Ocrevus 300 mg concentrate for solution for infusion, Kesimpta 20 mg solution for injection in pre-filled syringe, Ocrevus 300 mg concentrate for solution for infusion, MabThe

    Kyverna Therapeutics

    Primary or Secondary Progressive Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  42. Ketamine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule terminated

    1 trial

  43. Ketamine

    Grace Therapeutics

    Obstetric Pain

    phase 2 small molecule completed

    1 trial

  44. Ketamine Hydrochloride

    BRIGHT MINDS BIOSCIENCES INC.

    Depression

    phase 2 small molecule completed

    1 trial

  45. L-Glutamine

    BRIGHT MINDS BIOSCIENCES INC.

    Pulmonary Hypertension

    phase 2 small molecule completed

    1 trial

  46. L-Histidine, L-Histidine monohydrochloride monohydrate, Mannitol, Sucrose, Disodium EDTA dihydrate, Polysorbate 80, Water for injection

    Tour Hekla

    Thyroid Eye Disease

    phase 2 small molecule active

    1 trial

  47. L-citrulline

    United Therapeutics Europe Ltd

    Post Deployment Related Asthma

    phase 2 small molecule active

    1 trial

  48. LAAM

    BRIGHT MINDS BIOSCIENCES INC.

    Behavior Therapy

    phase 2 other completed

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources Β· All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.